Multiple myeloma is a relatively common hematologic malignancy, and the treatment of choice for this disease is chemotherapy. The first choice of chemotherapy is a combination of drugs, generally including the combination of melphalan and prednisone, the combination of carmustine, cyclophosphamide and prednisone, or the combination of carmustine, cyclophosphamide, melphalan, prednisone and vincristine, but the NCCN guidelines currently recommend bortezomib-based combination chemotherapy as the first-line treatment option. The efficacy of the treatment is evaluated according to the indicators of hematocrit, calcium gradually normalizing, serum M protein gradually disappearing, and urine protein negative, or some of the indicators are in remission. In parallel with chemotherapy, it is necessary to take local radiotherapy, which can reduce pain, reduce the pressure on the surrounding tissues, and also prevent pathological fractures.